Olpinat (Olanzapine)

Olanzapine, the active ingredient in Olpinat, is an atypical antipsychotic presented as a 10 mg tablet for oral use. It is prescribed for the management of schizophrenia and bipolar I disorder in adults. GNH USA supplies Olpinat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olpinat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olpinat is an atypical antipsychotic that acts on dopamine and serotonin pathways to treat serious mental health conditions.

- Schizophrenia: helps reduce hallucinations, delusions and thought disorder. - Bipolar I disorder (manic episodes): stabilises mood and diminishes manic symptoms. - Acute psychotic episodes: provides rapid symptom control in emergency settings. - Maintenance therapy for schizophrenia: supports long‑term relapse prevention. - Adjunctive treatment in major depressive disorder with psychotic features: augments antidepressant response. - Off‑label use for anxiety disorders: sometimes considered when other agents are ineffective.

Olpinat may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Weight gain: increased appetite and caloric intake. - Sedation: drowsiness or feeling unusually sleepy. - Metabolic changes: elevated blood glucose and lipid levels. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Orthostatic hypotension: light‑headedness on standing.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Tardive dyskinesia: involuntary, repetitive movements, often of the face. - Severe hyperglycaemia: diabetic ketoacidosis or hyperosmolar state. - Agranulocytosis: dangerously low white‑blood cell count. - Myocardial infarction or stroke: increased cardiovascular risk. - Seizures: especially in patients with a history of epilepsy.

Before initiating Olpinat, clinicians should evaluate patient history and monitor relevant parameters.

- Baseline metabolic assessment: record weight, fasting glucose and lipid profile. - Monitor for extrapyramidal symptoms: watch for involuntary movements. - Assess cardiovascular risk: check blood pressure and lipid levels regularly. - Review hepatic and renal function: adjust if significant impairment exists. - Pregnancy and lactation counseling: discuss potential risks and benefits. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Olpinat can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluoxetine, ciprofloxacin): increase olanzapine plasma levels. - CNS depressants (benzodiazepines, opioids): enhance sedation and respiratory depression. - Anticholinergic agents: may worsen dry mouth and constipation.

Moderate Interactions (Monitor Closely):\n- Smoking: induces CYP1A2, potentially lowering olanzapine concentrations. - Antihypertensive drugs: additive hypotensive effect. - Lithium: combined use may increase risk of neurotoxicity. - Diabetes medications: olanzapine‑induced hyperglycaemia may require dose adjustments. - QT‑prolonging agents: monitor ECG for arrhythmia risk.